Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

Clover Starts Phase III Trial of COVID Vaccine as a Booster to Other Vaccines

publication date: Jun 16, 2022

Shanghai Clover Biopharma has started a Phase III trial of its Trimer-Tag™ COVID vaccine as a booster following two doses of commonly administered COVID-19 vaccines. The trial will determine safety and immunogenicity of Clover’s SCB-2019 (CpG 1018/Alum) compared to a third dose of CoronaVac™ (Sinovac Inactivated Vaccine), Comirnaty® (Pfizer/BioNTech mRNA Vaccine), and Vaxzevria® (AstraZeneca Viral Vector Vaccine). Clover says SCB-2019 has shown efficacy against Omicron variants, and it expects the candidate will prove to be a universal COVID booster. More details....

Stock Symbol: (HK: 02197)

Share this with colleagues:  

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio Event
September 20-21 | Shanghai
September 25-26 | Digital
ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China